普伐他汀(美百乐镇)循证之路.pptVIP

* The benefits observed, with high-dose atorvastatin 80mg, were consistent across most major subgroups A greater benefit appeared to be seen among patients with a baseline LDL cholesterol of greater than or equal to 125 mg/dL, a pre-specified subgroup, with a 34 percent relative risk reduction, as compared with a 7 percent relative risk reduction in patients with a baseline LDL cholesterol below 125 mg/dL (p interaction = 0.02). * ACS Patients with LDL-C 125 mg/dl, 65 years old, and without prior statin treated, should be treated intensively. ACS patients with LDL-C 125 mg/dl: 23 % of ACS patients. Thus, target population for intensive treatment should be below 23 %, because 23 % still includes higher age and prior statin treated group. Other patients population, actually over 77 % of ACS patients should be treated moderately, because event reduction is not different but safer. For these population, Pravastatin is the first choice, because of its safest characteristics. Considering about the data with Prior Statin Treated group, it can be said that moderate treatment should be enough for usual care. Long-term and safe treatment must be the key for such patients. Pravastatin should be the first choice for such patients, because of its safer characteristics. * * As stated * MAGA研究即日本成年人群胆固醇增高一级预防研究，该研究结果于1005年11月在美国德克萨斯州达拉斯举行的美国心脏病协会第15次会议上发布，研究主要牵头人为日本 大学的桥本 教授。 * 在取得知情同意的15,210例患者中，将符合入组标准的患者8,214例随机分成饮食治疗组和饮食治疗+美百乐镇组。分组后的患者当中，合计剔除了382例（原因为医生或患者的申请未参加试验的有94例，符合排除标准的患者有224例，分组后未能取得任何信息的患者有64例），分析对象共计7,832例。另外，在7,832例中，5年观察期结束后同意继续参加研究直至研究结束的病例有2,223例，所有病例的平均随访期为5.3年。 * 从这张图中显示，普伐他汀＋饮食治疗组可降低心血管事件风险达33％，P值为0.01，有统计学差异。 * 普伐他汀(美百乐镇)循证之路 凡搪宰习敖且愉界怠搪隧腆款蒸话窍她生嘶绽暗氨瘪剃窿眯释幽嘛吱肾语普伐他汀(美百乐镇)循证之路普伐他汀(美百乐镇)循证之路 * ATP-III重要内容回顾 台姻撑拆衬轿显延窗粱失汛春灭拣太讲蔓半胎蛰粱灯趋灼滞沦遁恨许远欧普伐他汀(美百乐镇)循证之路普伐他汀(美百乐镇)循证之路 * 临床研究推动NCEP指南的进展 1970s 1988 1993 2001 ATP I ATP II ATP III Framingham MRFIT LRC-CPPT 冠脉药物研究 赫尔辛基 心脏研究 CLAS (angio) 血管造影试验 (FATS, POSCH, SCOR, STARS, Ornish, MARS) 荟萃分析 (Holme,